Corrigendum: Integrated bioinformatic analysis reveals TXNRD1 as a novel biomarker and potential therapeutic target in idiopathic pulmonary arterial hypertension

Lin, Wenchao; Tang, Yiyang; Zhang, Mengqiu; Liang, Benhui; Wang, Meijuan; Zha, Lihuang; Yu, Zaixin

doi:10.3389/fmed.2022.1116599

CORRECTION article

Front. Med., 15 December 2022

Sec. Pulmonary Medicine

Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.1116599

Corrigendum: Integrated bioinformatic analysis reveals TXNRD1 as a novel biomarker and potential therapeutic target in idiopathic pulmonary arterial hypertension

This article is a correction to:

Integrated Bioinformatic Analysis Reveals TXNRD1 as a Novel Biomarker and Potential Therapeutic Target in Idiopathic Pulmonary Arterial Hypertension
1. Read original article

$\nWenchao Lin$ Wenchao Lin

Meijuan Wang

Department of Cardiology, Xiangya Hospital, Central South University, Changsha, China

A corrigendum on
Integrated bioinformatic analysis reveals TXNRD1 as a novel biomarker and potential therapeutic target in idiopathic pulmonary arterial hypertension

by Lin, W., Tang, Y., Zhang, M., Liang, B., Wang, M., Zha, L., and Yu, Z. (2022). Front. Med. 9:894584. doi: 10.3389/fmed.2022.894584

In the published article, there was an error in the Funding statement “This study was supported by the National Natural Science Foundation of China (Nos. 8187011311, 81873416, and 8210012237) and the Key Research and Development Program of Hunan Province (2020SK2065).” The fund numbers (8187011311, 8210012237) were the initial acceptance numbers, not the final grant numbers. The correct Funding statement appears below.

Funding

This study was supported by the National Natural Science Foundation of China (Nos. 82070055, 81873416, and 82100071) and the Key Research and Development Program of Hunan Province (2020SK2065).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: bioinformatic analysis, TXNRD1, pulmonary hypertension, biomarker, RRA, GEO

Citation: Lin W, Tang Y, Zhang M, Liang B, Wang M, Zha L and Yu Z (2022) Corrigendum: Integrated bioinformatic analysis reveals TXNRD1 as a novel biomarker and potential therapeutic target in idiopathic pulmonary arterial hypertension. Front. Med. 9:1116599. doi: 10.3389/fmed.2022.1116599

Received: 05 December 2022; Accepted: 06 December 2022;
Published: 15 December 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Lin, Tang, Zhang, Liang, Wang, Zha and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zaixin Yu, yes yuzaixin@126.com; Lihuang Zha, yes zhalihuang@csu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.